Diuretics: Still the mainstay of treatment

Critical Care Medicine

Volumn 36, Issue 1 SUPPL., 2008, Pages

  Wang, David J ^a   Gottlieb, Stephen S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Acute decompensated heart failure; Diuretic therapy; Neurohormonal activation

Indexed keywords

ALDOSTERONE ANTAGONIST; BENDROFLUMETHIAZIDE; BUMETANIDE; CHLOROTHIAZIDE; DIURETIC AGENT; EPLERENONE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METOLAZONE; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ACUTE HEART FAILURE; ADD ON THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DIURESIS; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG MEGADOSE; HEARING LOSS; HORMONE ACTION; HUMAN; LOW DRUG DOSE; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 37549035406     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000296272.68078.6B     Document Type: Article

References (63)

1. Faris R, Flather MD, Purcell H, et al: Diuretics for heart failure. Cochrane Database Syst Rev 2006; (1):CD003838
2. Brater DC: Diuretic pharmacokinetics and pharmacodynamics. In: The In Vivo Study of Drug Action: Principles and Applications of Kinetic-Dynamic Modelling. Boxtel CJv, Holford NHG, Danhof M (Eds). Amsterdam, Elsevier, 1992, pp 253-275
3. Brater DC: Diuretic therapy. N Engl J Med 1998; 339:387-395
4. Gehr TW, Rudy DW, Matzke GR, et al: The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994; 56: 31-38
5. Vargo DL, Kramer WG, Black PK, et al: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995; 57:601-609
6. Schwartz S, Brater DC, Pound D, et al: Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. Clin Pharmacol Ther 1993; 54:90-97
7. Gottlieb SS, Khatta M, Wentworth D, et al: The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. Am J Med 1998; 104:533-538
8. Jackson EK. Diuretics. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics. Brunton LL (Ed). New York, McGraw-Hill, 2006, pp 737-769
9. Uchida T, Yamanaga K, Nishikawa M, et al: Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 1991; 205:145-150
10. Murray MD, Deer MM, Ferguson JA, et al: Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 2001; 111:513-520
11. Cosin J, Diez J: Torasemide in chronic heart failure: Results of the TORIC study. Eur J Heart Fail 2002; 4:507-513
12. Beermann B, Dalen E, Lindstrom B, et al: On the fate of furosemide in man. Eur J Clin Pharmacol 1975; 9:51-61
13. Brown CB, Ogg CS, Cameron JS, et al: High dose frusemide in acute reversible intrinsic renal failure: A preliminary communication. Scott Med J 1974; 19(Suppl 1):35-39
14. Rupp W: Pharmacokinetics and pharmacodynamics of Lasix. Scott Med J 1974; 19(Suppl 1):5-13
15. Vargish T, Benjamin R, Shenkman L: Deafness from furosemide. Ann Intern Med 1970; 72:761
16. Heidland A, Hennemann H, Rockel A, et al: Clinical pharmacology of high-dose furosemide in terminal renal insufficiency. Bratisl Lek Listy 1971; 56:620-629
17. Lahav M, Regev A, Ra'anani P, et al: Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102: 725-731
18. Kramer WG, Smith WB, Ferguson J, et al: Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol 1996; 36:265-270
19. Dormans TP, van Meyel JJ, Gerlag PG, et al: Diuretic efficacy of high dose furosemide in severe heart failure: Bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28:376-382
20. van Meyel JJ, Smits P, Dormans T, et al: Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994; 235:329-334
21. Morgan DB, Davidson C: Hypokalaemia and diuretics: An analysis of publications. BMJ 1980; 280:905-908
22. Shah KB, Rao K, Sawyer R, et al: The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005; 46:845-849
23. Juurlink DN, Mamdani MM, Lee DS, et al: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351:543-551
24. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717
25. Wilson JR, Reichek N, Dunkman WB, et al: Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981; 70:234-239
26. Robson AO, Kerr DN, Ashcroft R, et al: The diuretic response to frusemide. Lancet 1964; 13:1085-1088
27. Richardson A, Bayliss J, Scriven AJ, et al: Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet 1987; 2:709-711
28. Patterson JH, Adams KF Jr, Applefeld MM, et al: Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994; 14:514-521
29. Parker JO: The effects of oral ibopamine in patients with mild heart failure - A double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol 1993; 40:221-227
30. Bayliss J, Norell M, Canepa-Anson R, et al: Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57:17-22
31. Anand IS, Kalra GS, Harris P, et al: Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 1991; 2:273-278
32. Ellison DH: Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999; 19: 581-597
33. Almeshari K, Ahlstrom NG, Capraro FE, et al: A volume-independent component to postdiuretic sodium retention in humans. J Am Soc Nephrol 1993; 3:1878-1883
34. Wilcox CS, Mitch WE, Kelly RA, et al: Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983; 102:450-458
35. Hammarlund MM, Odlind B, Paalzow LK: Acute tolerance to furosemide diuresis in humans: Pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985; 233: 447-453
36. Wakelkamp M, Alvan G, Gabrielsson J, et al: Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60:75-88
37. Ellison DH, Velazquez H, Wright FS: Adaptation of the distal convoluted tubule of the rat: Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest 1989; 83:113-126
38. Kaissling B, Stanton BA: Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1988; 255:F1256-F1268
39. Ellison DH: The physiologic basis of diuretic synergism: Its role in treating diuretic resistance. Ann Intern Med 1991; 114:886-894
40. Loon NR, Wilcox CS, Unwin RJ: Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989; 36:682-689
41. DiBona GF, Sawin LL: Renal nerve activity in conscious rats during volume expansion and depletion. Am J Physiol 1985; 248:F15-F23
42. Petersen JS, DiBona GF: Effects of renal denervation on sodium balance and renal function during chronic furosemide administration in rats. J Pharmacol Exp Ther 1992; 262:1103-1109
43. Mizelle HL, Hall JE, Montani JP: Role of renal nerves in control of sodium excretion in chronic congestive heart failure. Am J Physiol 1989; 256:F1084-F1093
44. Kon V, Yared A, Ichikawa I: Role of renal sympathetic nerves in mediating hypoperfusion of renal cortical microcirculation in experimental congestive heart failure and acute extracellular fluid volume depletion. J Clin Invest 1985; 76:1913-1920
45. + transport. Am J Physiol 1988; 255:F1269-F1275
46. +-ATPase with furosemide administration. Am J Physiol 1987; 252:F910-F915
47. Mernissi GE, Doucet A: Stimulation of Na-K-ATPase in the rat collecting tubule by two diuretics: Furosemide and amiloride. Am J Physiol 1984; 247:F485-F490
48. Rudy DW, Voelker JR, Greene PK, et al: Loop diuretics for chronic renal insufficiency: A continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991; 115: 360-366
49. Aaser E, Gullestad L, Tollofsrud S, et al: Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest 1997; 57:361-367
50. Francis GS, Siegel RM, Goldsmith SR, et al: Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: Activation of the neurohumoral axis. Ann Intern Med 1985; 103:1-6
51. Ferguson JA, Sundblad KJ, Becker PK, et al: Role of duration of diuretic effect in preventing sodium retention. Clin Pharmacol Ther 1997; 62:203-208
52. Schuller D, Lynch JP, Fine D: Protocol-guided diuretic management: Comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 1997; 25: 1969-1975
53. Howard PA, Dunn MI: Aggressive diuresis for severe heart failure in the elderly. Chest 2001; 119:807-810
54. Oster JR, Epstein M, Smoller S: Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983; 99:405-406
55. Wollam GL, Tarazi RC, Bravo EL, et al: Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J Med 1982; 72:929-938
56. Fliser D, Schroter M, Neubeck M, et al: Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994; 46: 482-488
57. Knauf H, Mutschler E: Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997; 29:367-372
58. Knauf H, Mutschler E: Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26:394-400
59. Kiyingi A, Field MJ, Pawsey CC, et al: Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990; 335: 29-31
60. Channer KS, McLean KA, Lawson-Matthew P, et al: Combination diuretic treatment in severe heart failure: A randomised controlled trial. Br Heart J 1994; 71:146-150
61. Steinmuller ST, Puschett JB: Effects of metolazone in man: Comparison with chlorothiazide. Kidney Int 1972; 1:169-181
62. van Vliet AA, Donker AJ, Nauta JJ, et al: Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993; 71:21A-28A
63. Shankar SS, Brater DC: Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284: F11-F21